

ProteoTech to Present at The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders, to be held in Paris, France, June 7-11, 2009

Kirkland, WA, June, 2009 - ProteoTech Inc. announced today that Dr. Luke Esposito, Director of Neuroscience Research, will present at the 13th International Congress of Parkinson's Disease and Movement Disorders, to be held in Paris, France, June 7-11, 2009.

Dr. Luke Esposito on Sunday June 7 -Thursday June 11 will present during the "Parkinson's disease: Behavioral disorders" poster session. Dr. Esposito's presentation is entitled:

"SynuclereTM: Development of a Novel Small Molecule that Effectively Reduces Alpha-Synuclein Aggregation and Improves Motor Dysfunction".

SynuclereTM is a novel small molecule developed by ProteoTech that looks promising as a future disease-modifying treatment for Parkinson's disease and related disorders. ProteoTech's work in Parkinson's disease was partially funded by a LEAPS award from The Michael J. Fox Foundation for Parkinson's Research.

About ProteoTech: ProteoTech is a private drug development company located in the Seattle, WA area (Kirkland, WA), and is focused on targeting amyloid diseases. Besides *SynuclereTM* in late stage pre-clinical development for the treatment of Parkinson's disease, the Company is developing EXEBRYL-1[®] for the treatment of Alzheimer's disease, SystebrylTM for the treatment of Systemic Amyloidosis, and is in late stage pre-clinical development for a novel small peptide called **PeptiClereTM** for the treatment of Alzheimer's disease. For more information please see the Company web site at www.proteotech.com.